Image Place holder

Wade Jeffers Sexton, MD


Specialty: Urology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Sexton attended Furman University in Greenville, South Carolina as a scholar-athlete and graduated with a Bachelor of Science Degree in Biology. While at Furman, he was a member of Furman’s National Championship football team. He attended Emory University’s School of Medicine on an Air Force sponsored Health Professions Scholarship and then completed his general surgery and urology residency training at the Wake Forest University Baptist Medical Center. Following the completion of his residency, Dr. Sexton entered active duty military service with the United States Air Force and while on active duty, was selected to perform a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center. From 2001-2004, he served as Director of Urologic Oncology with the 59th Medical Wing at Wilford Hall USAF Medical Center in San Antonio, Texas. Thereafter, he joined Moffitt Cancer Center in Tampa, Florida, where he is now a Senior Member in the Department of Genitourinary Oncology and a Professor in the Department of Oncologic Sciences with the University of South Florida. Since 2008, he has served as Director of the Society of Urologic Oncology accredited fellowship at Moffitt Cancer Center. Dr. Sexton has held several leadership positions at Moffitt including an extended service on the Medical Executive Committee culminating as President of the Medical Staff from 2014-2016. He is a 2014 graduate of the inaugural Moffitt Cancer Center Leadership Academy. He has served in different capacities with the Florida Urologic Society (FUS) including president of the FUS from 2015-2016. He is a long-term member of the National Comprehensive Cancer Network (NCCN) guidelines panel for bladder and penile cancers, a faculty member for the American Urological Association (AUA) Annual Board Review Course (testicular cancer), and holds membership on both the Fellowship Committee and the Board of Directors for the Society of Urologic Oncology (SUO). He is primary investigator and collaborator on numerous clinical trials and grant funded translational studies, has authored over 100 manuscripts and book chapters, and maintains an extremely busy clinical practice focused towards bladder, kidney and testicular malignancies. Dr. Sexton has a special interest in minimally invasive kidney-sparing procedures, bladder reconstruction and nerve preservation surgery, as well as advanced urologic laparoscopic procedures. He was awarded a Meritorious Service Medal while on active duty with the United States Air Force. In 2013, it was a tremendous honor for him to be recognized as an MD Anderson Cancer Center Distinguished Alumnus. He has been recognized as a Top Doctor in Tampa Bay and repeatedly as one of America’s Top Physicians, Top Surgeons and Top Doctors for Cancer.

Education & Training

Board Certification:

  • Urology

Fellowship:

  • The University of Texas, MD Anderson Cancer Center - Urologic Oncology

Residency:

  • Wake Forest University, Winston-Salem, NC - Surgery
  • Wake Forest University, Winston-Salem, NC - Urology

Medical School:

  • Emory University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 18680
A study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: ALT-803; BCG
Open

CLINICAL TRIAL 17753
Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer
Condition: Genitourinary
Intervention:
Open

CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18536
Coordinated High Dose Interleukin-2 (aldesleukin, Proleukin) and Pembrolizumab (anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Condition: Genitourinary
Intervention: IL-2 (Interleukin-2); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18980
A Phase III, Multicenter, Randomized,Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiPd-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Placebo
Open

CLINICAL TRIAL 18787
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of Instiladrin (rAd-IFN/Syn3)Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: INSTILADRIN
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 May;103:148. Pubmedid: 28108090.
  • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 May. Pubmedid: 28566202.
  • Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May;8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May;103:142-148. Pubmedid: 28011275.
  • Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immun. 2017 Mar;66(3):403-410. Pubmedid: 27995306.
  • Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother. 2017 Mar;13(3):501-506. Pubmedid: 28085544. Pmcid: PMC5360147.
  • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence Free Survival for Patients with Penile Cancer. J Urol. 2017 Jun. Pubmedid: 28652123.
  • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul;105:108-112. Pubmedid: 28342928.
  • Leone AR, Kidd LC, Diorio GJ, Zargar-Shoshtari K, Sharma P, Sexton WJ, Spiess PE. Bilateral benign renal oncocytomas and the role of renal biopsy: single institution review. BMC Urol. 2017 Jan;17(1):6. Pubmedid: 28081704. Pmcid: PMC5234146.
  • Patel S, Hafez O, Sexton WJ, Edwards DA. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report. A A Case Rep. 2017 Feb;8(4):78-80. Pubmedid: 28195861.
  • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. Pubmedid: 28410909.
  • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr;35(4):657-663. Pubmedid: 27495912.
  • Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 03. Pubmedid: 28268170.
  • Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Ne. 2016 Oct;14(10):1213-1224. Pubmedid: 27697976. Pmcid: PMC5379654.
  • Sharma P, Keenan RJ, Sexton WJ. Mass in Solitary Intrathoracic Kidney Within Bochdalek Hernia. Urology. 2016 Nov;97:e15-e16. Pubmedid: 27554626.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov;34(11):1567-1573. Pubmedid: 27072536.
  • Zargar-Shoshtari K, Sexton WJ, Poch MA. Management of Urethral Recurrences: Urothelial and Nonurothelial. Urol Clin North Am. 2016 Nov;43(4):515-521. Pubmedid: 27717437.
  • Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May;387(10032):2008-2016. Pubmedid: 26969090. Pmcid: PMC4878938.
  • Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, Rathmell WK, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urol Oncol. 2016 Mar;34(3):122.e1-122.e7. Pubmedid: 26546482. Pmcid: PMC4761468.
  • Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA. Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma. BJU Int. 2016 Jun;117(6B):E60-E66. Pubmedid: 26118331.
  • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul;93:130-134. Pubmedid: 27041469.
  • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan;195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
  • Markow M, Bui MM, Lin HY, Lloyd M, Sexton WJ, Dhillon J. Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs. Pathol Oncol Res. 2016 Jan;22(1):115-120. Pubmedid: 26350056.
  • Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb;23(1):8127-8134. Pubmedid: 26892052.
  • Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Inform. 2016 Feb;15:23-28. Pubmedid: 26966347. Pmcid: PMC4768948.
  • Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb;14(1):89-95. Pubmedid: 26453395.
  • Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb;14(1):82-88. Pubmedid: 26411593.
  • Zargar-Shoshtari K, Ashouri K, Sharma P, Baumgarten A, Sexton WJ, Pow-Sang J, Spiess PE. Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ J Surg. 2016 Dec;86(1-2):44-48. Pubmedid: 26370725.
  • Patel S, Hafez O, Sexton WJ, Edwards DA. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide. A A Case Rep. 2016 Dec. Pubmedid: 27941483.
  • Sharma P, McCormick BZ, Zargar-Shoshtari K, Sexton WJ. Is surgeon intuition equivalent to models of operative complexity in determining the surgical approach for nephron sparing surgery?. Indian J Urol. 2016 Apr;32(2):124-131. Pubmedid: 27127355. Pmcid: PMC4831501.
  • Simon RM, Kim T, Espiritu P, Kurian T, Sexton WJ, Pow-Sang JM, Sverrisson E, Spiess PE. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015 Sep;41(5):911-919. Pubmedid: 26689516. Pmcid: PMC4756967.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct;33(10):1585-1592. Pubmedid: 25552207.
  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov;33(11):1763-1768. Pubmedid: 25774005.
  • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov;194(5):1220-1225. Pubmedid: 26055823.
  • Zargar-Shoshtari K, Sharma P, Espiritu P, Kurian T, Pow-Sang JM, Mangar D, Sexton WJ, Spiess PE. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. Urol Oncol. 2015 Mar;33(3):112.e23-112.e29. Pubmedid: 25555854.
  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):225-230. Pubmedid: 25544725.
  • Emtage JB, Agarwal G, Sexton WJ. Robotic-Assisted Renal Surgery. Cancer Control. 2015 Jul;22(3):291-300. Pubmedid: 26351884.
  • Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2015 Dec;15(12):1379-1387. Pubmedid: 26569509.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug;33(8):339.e17-339.e23. Pubmedid: 26094169.
  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug;116(2):196-201. Pubmedid: 25777366.
  • Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015 Aug;86(2):321-326. Pubmedid: 26187013.
  • Sharma P, Dhillon J, Agarwal G, Zargar-Shoshtari K, Sexton WJ. Disparities in Interpretation of Primary Testicular Germ Cell Tumor Pathology. Am J Clin Pathol. 2015 Aug;144(2):289-294. Pubmedid: 26185314.
  • Sharma P, Dhillon J, Sexton WJ. Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies. Urol Clin North Am. 2015 Aug;42(3):277-285. Pubmedid: 26216815.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug;22(4):7882-7889. Pubmedid: 26267026.
  • Baumgarten AS, Alhammali E, Hakky TS, Espiritu PN, Pow-Sang JM, Sexton WJ, Lockhart JL, Protzel C, Hakenberg O, Muneer A, Spiess PE. Salvage surgical resection for isolated locally recurrent inguinal lymph node metastasis of penile cancer: international study collaboration. J Urol. 2014 Sep;192(3):760-764. Pubmedid: 24603104.
  • Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martinw C, Moreno J, Kamat AM. Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial. J Urol. 2014 Jun;191(6):1721-1727. Pubmedid: 24342144.
  • Sverrisson EF, Kim T, Espiritu PN, Sexton WJ, Pow-Sang JM, Dhillon J, Spiess PE. The merits of cytology in the workup for upper tract urothelial carcinoma - a contemporary review of a perplexing issue. Int Braz J Urol. 2014 Jul;40(4):493-498. Pubmedid: 25251966.
  • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 2014 Jul. Pubmedid: 24893916.
  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul;32(5):619-624. Pubmedid: 24495448.
  • Hakky TS, Baumgarten AS, Allen B, Lin HY, Ercole CE, Sexton WJ, Spiess PE. Zonal NePhRO Scoring System: A Superior Renal Tumor Complexity Classification Model. Clin Genitourin Cancer. 2014 Feb;12(1):e13-e18. Pubmedid: 24120084.
  • Dhillon J, Mohanty SK, Kim T, Sexton WJ, Powsang J, Spiess PE. Spectrum of renal pathology in adult patients with congenital renal anomalies-a series from a tertiary cancer center. Ann Diagn Pathol. 2014 Feb;18(1):14-17. Pubmedid: 24321461.
  • Emtage, J.B., Buethe, D.D., Russell, C.M., Sexton, W.J.. Initial experience with robot-assisted retroperitoneal partial nephrectomy for suspected renal cell carcinoma. J Robotic Surg. 2014 Dec;8(4):305-311.
  • Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014 Aug;66(2):265-272. Pubmedid: 24630419.
  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug;192(2):350-356. Pubmedid: 24530987.
  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr;111(1):126-131. Pubmedid: 24746567.
  • Russell CM, Buethe DD, Dickinson S, Sexton WJ. Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. Ann Clin Lab Sci. 2014 Apr;44(1):91-98. Pubmedid: 24695481.
  • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2013 May;11(5):594-615. Pubmedid: 23667209. Pmcid: PMC4042432.
  • Sexton WJ. Editorial comment. Urology. 2013 Aug;81(6):1244. Pubmedid: 23608665.
  • Buethe DD, Sexton WJ, Greene JN, Changcharoen B, Kue-A-Pai P. Infections in Oncology: Urosepsis Due to Fluoroquinolone-Resistant Escherichia coli After Ultrasonographic-Guided Transrectal Implantation of Fiducial Markers. Cancer Control. 2013 Jul;20(3):233-236. Pubmedid: 23811707.
  • Sexton WJ. Editorial comment. J Urol. 2013 Jan;189(1 Suppl):S18. Pubmedid: 23234623.
  • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr;11(4):446-475. Pubmedid: 23584347.
  • Buethe DD, Moussly S, Lin HY, Yue B, Rodriguez AR, Spiess PE, Sexton WJ. Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney?. J Urol. 2012 Sep;188(3):729-735. Pubmedid: 22819418.
  • Seifert RP, McNab P, Sexton WJ, Sawczyn KK, Smith P, Coppola D, Bui MM. Rhabdomyomatous differentiation in Wilms tumor pulmonary metastases: a case report and literature review. Ann Clin Lab Sci. 2012 Oct;42(4):409-416. Pubmedid: 23090738.
  • Lawindy SM, Kurian T, Kim T, Mangar D, Armstrong PA, Alsina AE, Sheffield C, Sexton WJ, Spiess PE. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int. 2012 Oct;110(7):926-939. Pubmedid: 22540179.
  • Henderson-Jackson E, Sexton W, Zhang J, Hakam A, Petrovskyy VS, Bui MM, Chuang ST. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann Clin Lab Sci. 2012 Feb;42(1):81-88. Pubmedid: 22371914.
  • Spiess PE, Kurian T, Lin HY, Rawal B, Kim T, Sexton WJ, Pow-Sang JM. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012 Dec;110(11 pt B):E470-E474. Pubmedid: 22519938.
  • Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY, Spiess PE. Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 2012 Dec;110(11 pt B):E475-E480. Pubmedid: 22564727.
  • Kolla SB, Spiess PE, Sexton WJ. Interobserver reliability of the RENAL nephrometry scoring system. Urology. 2011 Sep;78(3):592-594. Pubmedid: 21782219.
  • Caso J, Tidwell J, Tsivian M, Sexton WJ. Stapled renal vein with in situ tumor thrombus: a useful intraoperative maneuver to facilitate radical nephrectomy and inferior vena cava thrombectomy. Urology. 2011 Jan;77(1):217-222. Pubmedid: 20472275.
  • Buethe DD, Sexton WJ. Bladder cancer: validating the EORTC risk tables in BCG-treated patients. Nat Rev Urol. 2011 Aug;8(9):480-481. Pubmedid: 21844905.
  • Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. Int Braz J Urol. 2010 Sep;36(5):571-582. Pubmedid: 21044374.
  • Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dickinson SI, Kang LC. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010 Oct;17(4):256-268. Pubmedid: 20861813.
  • Kolla SB, Ercole C, Spiess PE, Pow-Sang JM, Sexton WJ. Nephron-sparing surgery for pathological stage T3b renal cell carcinoma confined to the renal vein. BJU Int. 2010 Nov;106(10):1494-1498. Pubmedid: 20230378.
  • Sexton WJ. Editorial comment. J Urol. 2010 Mar;183(3):969-. Pubmedid: 20089275.
  • Caso J, Qin D, Sexton WJ. Eosinophilic cystitis following immediate post-resection intravesical instillation of mitomycin-C. Can J Urol. 2010 Jun;17(3):5223-5225. Pubmedid: 20566021.
  • Correa JJ, Hakky TS, Spiess PE, Chuang T, Sexton WJ. Robotic-assisted partial cystectomy with en bloc excision of the urachus and the umbilicus for urachal adenocarcinoma. J Robot Surg. 2010 Jan;3(4):235-238. Pubmedid: 27628636.
  • Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):953-959. Pubmedid: 20332277. Pmcid: PMC2852495.
  • Caso J, Seigne J, Back M, Spiess PE, Pow-Sang J, Sexton WJ. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol. 2009 Sep;182(3):887-893. Pubmedid: 19616230.
  • Moul J, Wu H, Sun L, McLeod D, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen onlyrecurrence of prostate cancer after radical prostatectomy. J Urol. 2008 May;179(5 Suppl):S53-S59. Pubmedid: 18405753.
  • Whittemore D, Hick E, Carter M, Moul J, Miranda-Sousa A, Sexton W. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008 Feb;179(2):516-522. Pubmedid: 18076949.
  • Rollison DE, Sexton WJ, Rodriguez AR, Kang LC, Daniel R, Shah KV. Lack of BK virus DNA sequences in most transitional-cell carcinomas of the bladder. Int J Cancer. 2007 Mar;120(6):1248-1251. Pubmedid: 17192899.
  • Al-Qudah H, Rodriguez A, Sexton W. Laparoscopic management of kidney cancer: updated review. Cancer Control. 2007 Jul;14(3):218-230. Pubmedid: 17615527.
  • Morey A, Evans L, McDonough RC 3rd, Park A, Sexton W, Basler J, SantucciRA, Amling C, O'Reilly K. Evaluation of mechanical bowel preparation methods in urinary diversion surgery. Can J Urol. 2006 Oct;13(5):3250-3254. Pubmedid: 17076946.
  • Montie J, Abrahams N, Bahnson R, Eisenberger M, El-Galley R, Herr H, Hudes G, Kuzel T, Lange P, Patterson A, Pollack A, Richie J, Sexton W, Shipley W, Small E, Trump D, Walther P, Wilson T. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov;4(10):984-1014. Pubmedid: 17112448.
  • Rodriguez A, Kang L, Politis C, Wade M, Sexton W, Miranda-Sousa A, Pow-Sang JM. Delayed metastatic renal carcinoma to prostate. Urology. 2006 Mar;67(3):623-623. Pubmedid: 16527593.
  • Rodriguez A, Sexton W. Management of locally advanced renal cell carcinoma. Cancer Control. 2006 Jul;13(3):199-210. Pubmedid: 16885916.
  • Rodriguez A, Burday D, Sexton W, Ahmad N, Pow-Sang J. Urothelial carcinoma in a child. Arch Esp Urol. 2005 Jun;58(5):473-475. Pubmedid: 16078794.
  • Baughman S, Sexton W, Glanton C, Dalrymple N, Bishoff J. Computerized tomography guided radio frequency ablation of a renal cell carcinoma within a renal allograft. J Urol. 2004 Oct;172(4 Pt 1):1262-1263. Pubmedid: 15371819.
  • Wu H, Sun L, Moul J, Wu H, McLeod D, Amling C, Lance R, Kusuda L, DonahueT, Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004 Mar;171(3):1111-1116. Pubmedid: 14767282.
  • Moul J, Wu H, Sun L, McLeod D, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141-1147. Pubmedid: 14767288.
  • Amling C, Riffenburgh R, Sun L, Moul J, Lance R, Kusuda L, Sexton W, Soderdahl D, Donahue T, Foley J, Chung A, McLeod D. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb;22(3):439-445. Pubmedid: 14691120.
  • Carter C, Donahue T, Sun L, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul J. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003 Nov;21(21):4001-4008. Pubmedid: 14581423.
  • Moul J, Sun L, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, KusudaL, Chung A, Soderdahl D, Donahue T. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol. 2003 Nov;21(6):447-455. Pubmedid: 14693271.
  • Massengill J, Sun L, Moul J, Wu H, McLeod D, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003 May;169(5):1670-1675. Pubmedid: 12686805.
  • Baughman S, Sexton W, Bishoff J. Multiple intravesical linear staples identified during surveillance cystoscopy after laparoscopic nephroureterectomy. Urology. 2003 Aug;62(2):351-351. Pubmedid: 12893356.
  • Sexton W, Wood C, Kim R, Pisters L. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol. 2003 Apr;169(4):1353-1356. Pubmedid: 12629359.
  • Moul J, Wu H, Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Rich N. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 2002 Aug;132(2):213-219. Pubmedid: 12219014.
  • Sexton W, Lance R, Reyes A, Pisters P, Tu S, Pisters L. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001 Aug;166(2):521-525. Pubmedid: 11458058.
  • Holmes R, Sexton W, Applewhite J, Kennedy M, Assimos D. Glycolate metabolism by Hep G2 cells. J Am Soc Nephrol. 1999 Nov;10:S345-S347. Pubmedid: 10541260.
  • Sexton W, Assimos D. Diagnostic and therapeutic laparoscopy for the adult cryptorchid testicle. Tech Urol. 1999 Mar;5(1):24-28. Pubmedid: 10374791.
  • Sexton W, Benedict J, Jarow J. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol. 1998 Mar;159(3):811-815. Pubmedid: 09474156.
  • Sexton W, Routh W, McCullough D, Bare R. Hypogastric arterial-ureteral fistula. J Urol. 1998 Jan;159(1):196-197. Pubmedid: 09400472.
  • Sexton W, Jarow J. Effect of diabetes mellitus upon male reproductive function. Urology. 1997 Apr;49(4):508-513. Pubmedid: 09111618.
  • Poore RE, Sexton WJ, Hart LJ, Assimos DG. Is radiographic evaluation of the chest necessary following flank surgery?. J Urol. 1996 Mar;155(3):849-851. Pubmedid: 8583591.
  • Poore R, Sexton W, Hart L, Assimos D. Is radiographic evaluation of the chest necessary following flank surgery. J Urol. 1996 Mar;155(3):849-851. Pubmedid: 08583591.
  • Rao SR, Moussly S, Pacheco M, Spiess PE, Sexton WJ. Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. Int Braz J Urol. 40(5):637-643. Pubmedid: 25498274.
  • Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann. 8(2):151-156. Pubmedid: 27141183. Pmcid: PMC4839230.
  • Abarzua-Cabezas FG, Sverrisson E, Cruz Rde L, Spiess PE, Haddock P, Sexton WJ. Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol. 41(1):147-154. Pubmedid: 25928521. Pmcid: PMC4752068.